Controlled Fluid Removal in Critical Ill Patients With Fluid Overload in the Intensive Care Unit.

Launched by MORTEN H. BESTLE · Nov 25, 2019

Keywords

ClinConnect Summary

This clinical trial is studying the effects of a medication called furosemide, which helps remove excess fluid from the body, in critically ill patients who have too much fluid in their system. The trial is comparing the results of patients receiving furosemide to those receiving a placebo (a treatment that does not contain the active medication). The goal is to see how well furosemide works in helping these patients get rid of excess fluid safely.

To be eligible for this trial, patients must be at least 18 years old, currently admitted to the intensive care unit, and have a fluid overload of at least 5% of their ideal body weight. Participants will receive treatment until the extra fluid is removed from their bodies. It’s important to note that patients with certain conditions, such as severe kidney problems or ongoing life-threatening issues, cannot participate. If you or a loved one is in the ICU and meets these criteria, this study could help improve our understanding of managing fluid overload in critically ill patients.

Gender

ALL

Eligibility criteria

• • Inclusion Criteria: ALL below must be met.
• • Acute admission to the intensive care unit.
• • Age ≥ 18 years of age
• • Fluid overload ≥ 5% of ideal body weight. If possible, all fluids administered before admission to the intensive care unit are to be included in the calculation of cumulative fluid balance.
• • Clinical stable (minimum criteria: MAP \> 50 mmHg and maximum infusion of 20 microgram/kg/minute of noradrenaline and lactate \< 4.0 mmol/L)
• Exclusion Criteria:
• • Known allergy to furosemide or sulphonamides.
• • Known pre-hospitalization advanced chronic kidney disease (eGFR \< 30 mL/minute/1.73 m\^2 or chronic RRT).
• • Ongoing renal replacement therapy.
• • Anuria \> 6 hours.
• • Rhabdomyolysis with indication for forced diuresis
• • Ongoing life-threatening bleeding as these patients need specific fluid/blood product strategies.
• • Acute burn injury of more than 10% of the body surface area as these patients need a specific fluid strategy.
• • Severe dysnatremia (p-Na \< 120 or \> 155 mmol/L) as these patients need a specific fluid strategy.
• • Severe hepatic failure as per the clinical team.
• • Patients undergoing forced treatment.
• • Fertile women (women \< 50 years) with positive urine human chorionic gonadotropin (hCG) or plasma-hCG.
• • Consent not obtainable as per the model approved for the specific trial site.